Skip to main content
ABVXAbivax SASell4.8·$82.10
SellModerate Confidence
Investment thesis

Abivax is a clinical-stage biotech burning cash at 2,697% of revenue with repeated earnings misses, offset by 89% analyst upside and a reward-to-risk of 6.89 after a 42% drawdown.

Thesis pillars

  • Extreme Cash Burn→Stable
  • Large Analyst Upside Binary Outcome→Stable
  • Persistent Earnings Misses→Stable
  • +2 more pillars — see the Why tab for full reasoning

Pillars as of Nov 1, 2026

Full reasoning →

Open full analysis

Abivax SA (ABVX) Stock Analysis

SellVALUE-TRAP 1/5ShortModerate Confidence

Healthcare · Biotechnology

Sell if holding. Engine safety override at $82.10: Quality below floor (3.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 7.8:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Below long-term trend.

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in... Read more

$82.10+73.3% A.UpsideScore 4.8/10#177 of 240 Biotechnology
QualityF-score4 / 9FCF yield-1.75%
Stop $79.38Analyst target $142.32(−13% haircut)A.R:R 7.8:1
Analyst consensus$163.58+99.2%12 analysts with price targets
$142.32Analyst target
$82.10price
$163.58mean
$181

Sell if holding. Engine safety override at $82.10: Quality below floor (3.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 7.8:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Below long-term trend. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.8/10, moderate confidence.

Passes 7/9 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 124d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: speculative.

news + 30-day 8-K events · 5-min refresh

Recent developments

No fresh coverage since Nov 3, 2026

Recent Developments — Abivax SA

Latest news

Latest item Nov 3, 2026 · Generated 2026-11-18T12:02:24Z.

TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Mon, Mar 22, 2027124d to earnings· next earnings call

Thesis

Rewards
No bull case signals
Risks
Quality below floor (3.7 < 4.0)

Key Metrics

P/E (TTM)—
P/E (Fwd)-21.4
Mkt Cap$7.2B
EV/EBITDA-21.1
Profit Mgn0.0%
ROE-252.3%
Rev Growth-6.8%
Beta-0.33
DividendNone
Analysts with ratings14

Quality Signals

Piotroski F4/9MoatNarrow

Options Flow

P/C0.74neutral
IV66%elevated

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

3 floor-breakers·1 ceiling hit

Revenue shrinking — -6.8% YoY. Growth thesis broken unless recovery story develops.static

Revenue Growth
0.8
Declining revenue: -7%
Low model confidence on this dimension (33%).

No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static

Earnings History
0.0
Surprise Avg
0.0
Erm
5.0
Earnings Timing
5.0
Earnings concerns: 1B/3M

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Roa
0.0
Net Margin
0.0
Fcf Quality
0.0
Rule Of 40
3.0
Piotroski F
4.4
Moat
5.5
Current Ratio
7.0
Gross Margin
10.0
Cash-burning: FCF -2697% of revenueRule of 40: -2704 (fail)
GatesMomentum 4.3<4.5Death cross (50MA < 200MA)A.R:R 7.8 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 124d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Speculative
RSI
38 · Neutral
↓ 20D MA↓ 50D MA↓ 200D MADEATH CROSSSupport $81.83Resistance $96.39

Price Targets

$79
$142
A.Upside+73.3%
A.R:R7.8:1

Position Sizing

ConvictionNone
Suggested %0%
Max %0%
RegimeSteady

Risk Alerts

! Quality below floor (3.7 < 4.0)
! momentum at 4.3 (below the engine's 4.5 threshold)
! Death cross — 50-day MA below 200-day MA

Earnings

B
M
M
M
1/4 beats
Next Earnings2027-03-22 (124d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is ABVX stock a buy right now?

Sell if holding. Engine safety override at $82.10: Quality below floor (3.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 7.8:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Below long-term trend. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $79.38. Score 4.8/10, moderate confidence.

What is the ABVX stock price target?

Analyst target: $142.32 (+73.3% upside). Prior stop was $79.38. Stop-loss: $79.38.

What are the risks of investing in ABVX?

Quality below floor (3.7 < 4.0).

Is ABVX overvalued or undervalued?

Abivax SA trades at a P/E of N/A (forward -21.4). TrendMatrix value score: 9.0/10. Verdict: Sell.

What do analysts say about ABVX?

14 analysts rate ABVX, with a consensus score of 4.2/5. 12 analysts publish price targets averaging $164.

What does Abivax SA do?ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural...

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.

Related stocks: ARGX (argenx SE) · HALO (Halozyme Therapeutics, Inc.) · ASND (Ascendis Pharma A/S) · ONC (BeOne Medicines Ltd.) · MGTX (MeiraGTx Holdings plc)
Home › Stocks › ABVX

Latest news

Latest News

Fiscal.ai15d ago
Benzinga26d ago
Benzinga28d agoAnalyst
Fiscal.ai29d agoAnalyst
Benzinga29d agoAnalyst
Benzinga36d ago
Benzinga49d agoProduct
Benzinga57d agoAnalyst
Benzinga57d agoAnalyst
Benzinga57d agoAnalyst
Benzinga58d agoEarnings
Benzinga58d agoEarnings
Benzinga58d ago
Benzinga58d ago
Benzinga65d agoEarnings
Benzinga69d agoAnalyst
Benzinga111d agoFda Decision
Benzinga124d agoMerger Acquisition
Benzinga132d ago
Benzinga132d agoAnalyst
Loading more...